WHANIN PHARM CO.,LTD Logo

WHANIN PHARM CO.,LTD

Develops and sells pharmaceuticals, specializing in CNS, cardiovascular, and GI drugs.

016580 | KO

Overview

Corporate Details

ISIN(s):
KR7016580003
LEI:
Country:
South Korea
Address:
서울특별시 송파구 법원로6길 11 (문정동, 환인빌딩), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Whanin Pharm Co., Ltd. is a pharmaceutical company focused on the development, manufacturing, and sale of therapeutic products. The company specializes in medications for the Central Nervous System (CNS), offering a range of neuropsychiatric drugs including anti-depressants, anti-psychotics, and nootropics. In addition to its core CNS portfolio, Whanin Pharm also produces pharmaceuticals for other therapeutic categories such as cardiovascular and gastrointestinal treatments, as well as antibiotics. The company actively engages in research and development to create innovative medications, extending its focus beyond CNS to the broader healthcare sphere.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.7 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-01 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.9 KB
2025-07-11 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 19.7 KB
2025-07-07 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 30.6 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-04-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.9 KB
2025-03-21 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.8 KB
2025-03-21 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.9 KB
2025-03-13 00:00
Audit Report / Information
감사보고서제출
Korean 20.1 KB
2025-03-13 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.8 MB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 830.1 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 4.9 KB
2025-02-28 00:00
Notice of Dividend Amount
현금ㆍ현물배당결정
Korean 8.4 KB
2025-02-28 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 13.7 KB

Automate Your Workflow. Get a real-time feed of all WHANIN PHARM CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WHANIN PHARM CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WHANIN PHARM CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF

Talk to a Data Expert

Have a question? We'll get back to you promptly.